William J. Peppard, PharmD, explains how emerging suzetrigine findings after knee arthroplasty connect opioid stewardship with functional recovery and the pharmacist’s role in ensuring treatment access.
|Podcasts|July 29, 2022
Pharmacy Focus: Psychedelic Pharmacy - Investigating Ketamine for Chronic Pain Management, Addiction Treatment
This month, we spoke with Tiago Reis Marques, MD, PhD, CEO of Pasithea Therapeutics, about ketamine and the future of the opioid epidemic.
Advertisement
This month, we spoke with Tiago Reis Marques, MD, PhD, CEO of Pasithea Therapeutics, about how investigative psychedelic treatments could help treat both chronic pain as well as addiction, and what this could mean for the future of the opioid epidemic.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
SubscribeAdvertisement
Related to this article
September’s pain management coverage examined postoperative nonopioid options, lessons from sickle cell pain research, and pharmacists’ experiences with controlled-substance prescribing.
Growing evidence points to gallstones and cholecystitis as an underrecognized risk of GLP-1 RA therapy—pharmacists are well positioned to catch it early.
Investigational inhaled stem cells for COPD raise questions about lasting clinical benefit and the pharmacy controls needed to deliver a living-cell product through a nebulizer.
A suspected plague death in Russia has renewed attention on the rare infection. Here's how to spot pneumonic plague and which antibiotics the CDC recommends.
In an interview with Pharmacy Times, Abdulkader Rahmo, PhD, discusses investigational inhaled cell therapy for COPD, the evidence needed to establish lasting clinical benefit, and pharmacists’ potential role in its delivery.
The gap is not a paperwork inconvenience—it is a cash flow problem with clinical consequences.
A meta-analysis of 27 trials found 15% lower cardiovascular (CV) event risk per 10-mm Hg SBP reduction, with eGFR declines but no rise in kidney failure.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pneumonic Plague: Symptoms, Antibiotics, and Current US Risk
2
Rising Gallbladder Complications With GLP-1 Receptor Agonists Call for Closer Pharmacist Monitoring
3
Intensive BP Control Cuts CV Risk Regardless of CKD Status
4
Inside the New Consensus Recommendations for Acute Stroke Care
5